The Future of Chimeric Antigen Receptor T Cell Therapy.
The Future of Chimeric Antigen Receptor T Cell Therapy.
复制标题
嵌合抗原受体 T 细胞疗法的未来。
DOI：
10.1016/j.hoc.2023.06.005
复制
发表时间：
2023
期刊：
影响因子：
--
通讯作者：
Smith,EricL
中科院分区：
文献类型：
--
作者：
Smith,EricL
在过去的10年中，CAR T细胞疗法已被证明对B细胞和浆细胞恶性肿瘤具有变革性作用，但该领域才开始意识到这种疗法对患者的潜在益处。在接下来的10年里，预计将在B/浆细胞恶性肿瘤患者的持久反应率方面取得进展;扩展到T细胞，骨髓和实体恶性肿瘤;以及在交付和制造方面改变该领域。
Over the last 10 years CAR T cell therapies have been shown to be transformative for B-and plasma-cell malignancies, however the field is only beginning to realize the potential benefit to patients of such therapies. Over the next 10 years it is expected that advances will be made in durable response rates for patients with B/plasma cell malignancies; expansion to T-cell, myeloid, and solid malignancies; and in delivery and manufacturing to transform the field.